The EAG considered that results from the SPR1NT trial supported the company’s conclusion that onasemnogene abeparvovec is a clinically effective treatment for babies with pre-symptomatic SMA and two or three copies of the SMN2 gene. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.